WeMed Medical Engages in National Healthcare Pricing Guidelines Release
Released by China's National Healthcare Security Administration in January 2026, the "Guidelines for Pricing Surgical and Therapeutic Auxiliary Operations (Trial)" establish a unified pricing framework for advanced auxiliary services. The guidelines specifically address technologies like surgical robotics and telesurgery, integrating the latest medical advancements into the national pricing system.
A leader in China's high-end medical equipment sector, WeMed Medical stood out as one of the select few companies invited to both exhibit and attend the official release event. This dual role allowed it to showcase proprietary innovations while actively contributing to the formulation of industry benchmarks, thereby affirming the critical role of homegrown enterprises in advancing medical technology.
From a national strategic viewpoint, the continuous revision of the medical service pricing guidelines constitutes a key reform within the healthcare security system and a strategic initiative designed to enable industrial advancement.
The recently issued Auxiliary Operation Guidelines represent the first national-level systematic regulation of surgical robotics. By categorizing "surgical robotic arm assistance" and "remote surgery" as independent auxiliary procedural units, the guidelines depart from the traditional site-specific pricing model. They establish a clear framework for tiered pricing based on technical complexity and additional charges for specialized intraoperative services. This creates a unified and transparent pricing structure for precision medical devices such as vascular interventional robots, addressing previous policy gaps in the clinical pricing of intelligent interventional equipment. Through this policy-driven approach, the guidelines steer the industry toward greater precision and intelligence, opening significant pathways for domestic high-end medical equipment to overcome technical bottlenecks and achieve scalable clinical implementation.
WeMed Medical's dual participation in the event not only demonstrated domestic innovation capability but also reflected the company's active role in China's healthcare reform. In the exhibition area, WeMed Medical featured its vascular interventional surgical robot, which incorporates the world's first integrated "hand-eye-brain" technological architecture. The system achieves high-precision sensing and sub-millimeter motion control, supported by AI models and a vast clinical database to create a fully immersive surgical environment. This advancement marks a shift in interventional surgery from the manual era to an intelligent, technology-driven paradigm.
